Publications by authors named "John DelBianco"

Non-native snake envenomations can be difficult to manage because of challenges obtaining appropriate antivenom and unfamiliarity with the expected clinical effects. This case report describes a 37-year-old man who was envenomated by his pet monocled cobra (). He experienced respiratory failure, requiring intubation and mechanical ventilation.

View Article and Find Full Text PDF
Article Synopsis
  • * A retrospective analysis of patient records was conducted, revealing that most patients were children (under 10 years old) and predominantly Hispanic, with the majority arriving at the emergency department within an hour of exposure.
  • * The incident demonstrates the urgent need for CO detectors in daycares to enhance safety, provide early warnings, and improve response readiness for similar emergencies in the future.
View Article and Find Full Text PDF

Veterinary medication exposure may result in human toxicity, with approximately 6,000 exposures to veterinary-only medications reported to poison centers in 2022. There is a paucity of literature on the management of poisoned patients secondary to pharmaceuticals intended for equine use. Pergolide is a dopamine and serotonin receptor agonist and is currently approved to treat equine Cushing's disease.

View Article and Find Full Text PDF

Diazoxide is the only medication approved by the United States Food and Drug Administration for the treatment of hyperinsulinism-induced hypoglycemia. Overdose is infrequently reported. This case describes a preterm four-week-old male who was prescribed diazoxide and chlorothiazide for perinatal stress-induced hyperinsulinism.

View Article and Find Full Text PDF

Background: Acute pain is a leading reason for Emergency Department (ED) evaluation, accounting for nearly half of all ED visits. Therefore, providing effective non-opioid analgesics in the ED is critical. Oral acetaminophen (APAP) is commonly administered in the ED but is limited to patients tolerating oral intake.

View Article and Find Full Text PDF

Purpose: Apixaban is a direct-acting oral anticoagulant that selectively inhibits factor Xa. Reversal strategies utilized to treat factor Xa inhibitor-associated bleeding include andexanet alfa, prothrombin complex -concentrate (PCC), and activated PCC (aPCC). The optimal treatment of traumatic intracranial hemorrhage in the setting of an apixaban overdose is unknown.

View Article and Find Full Text PDF

Objective: Epilepsy affects ~50 million people worldwide causing significant medical, financial, and sociologic concerns for affected patients and their families. To date, treatment of epilepsy is primarily symptomatic management because few effective preventative or disease-modifying interventions exist. However, recent research has identified neurobiological mechanisms of epileptogenesis, providing new pharmacologic targets to investigate.

View Article and Find Full Text PDF